48P The A2AR antagonist inupadenant promotes humoral responses in preclinical models
A2A receptor (A2AR) is a key mediator of adenosine immunosuppression. Inupadenant is a highly selective A2AR antagonist, which maintains full potency at the high levels of adenosine found in tumors. We recently reported that B cells are a novel cellular target of inupadenant (Martinoli et al., AACR 2023). Here, we further investigate how inupadenant modulates humoral responses in vitro, ex vivo and in vivo.
Authors
- Paola Tieppo
- Su‐Jin Jung (ORCID: https://orcid.org/0000-0003-1103-7477)
- Yvonne McGrath (ORCID: https://orcid.org/0000-0001-6564-7700)
- Francesco Strozzi (ORCID: https://orcid.org/0000-0002-6845-6982)
- Lucas Martins Chaible (ORCID: https://orcid.org/0000-0002-9645-2663)
- Hussein Shehade (ORCID: https://orcid.org/0000-0003-4052-6309)
- Reece Marillier
- Maria Lucia Rosa Rossetti
- M. Mercier
- David Carbonez (ORCID: https://orcid.org/0009-0003-3276-8153)
- M-C. Dieu-Nosjean
Institutions
- Délégation Paris 5 (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Bone Therapeutics (BE)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.101008
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00